In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function.
Article Details
- CitationCopy to clipboard
Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA
In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function.
Eur J Pharmacol. 2004 Jan 1;483(1):45-53.
- PubMed ID
- 14709325 [ View in PubMed]
- Abstract
In vivo microdialysis was used to monitor the effects of oral aripiprazole and olanzapine on basal extracellular concentrations of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and 5-hydroxyindole acetic acid (5-HIAA) in the medial prefrontal cortex and striatum of conscious, freely moving rats. Acute aripiprazole administration did not affect dopamine output, but produced moderate increases in DOPAC and HVA concentrations, in medial prefrontal cortex or striatum of drug-naive rats. Similarly, aripiprazole did not affect dopamine output but produced moderate elevations in DOPAC and HVA concentrations in the striatum of chronic aripiprazole-pretreated rats. Olanzapine produced comparatively larger elevations in dopamine, DOPAC, and HVA in both regions, which, in the striatum, were diminished after chronic olanzapine exposure. Aripiprazole reduced extracellular 5-HIAA concentrations in the medial prefrontal cortex and striatum of drug-nai;ve rats, but not in chronic aripiprazole-pretreated rats. Together, these data provide in vivo evidence of aripiprazole-induced changes in forebrain dopaminergic and serotonergic function that may reflect its partial agonist activity at presynaptic dopamine D(2) and 5-HT(1A) receptors and antagonist activity at 5-HT(2A) receptors.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Aripiprazole 5-hydroxytryptamine receptor 1A Protein Humans UnknownPartial agonistDetails Aripiprazole lauroxil 5-hydroxytryptamine receptor 1A Protein Humans YesPartial agonistDetails